Japan Approves Continued Use Of Strattera For AD/HD Patients Over 18
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare June 15 notified Eli Lilly's Japan subsidiary it expanded labeling for Strattera (atomoxetine), allowing the drug to be used continuously for patients over 18 years. Currently, Strattera is indicated for attention-deficit hyperactivity disorder for patients aged 6 to 18. However, the change only applies to patients who have started taking the drug before the age of 18 and need to continue the treatment. Eli Lilly is conducting a Phase III trial of Strattera on adult patients. Many AD/HD patients in Japan have expressed a desire to continue the medication even after they turn 18. (Click here for more - Japanese language)
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.